

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
29 January 2004 (29.01.2004)

PCT

(10) International Publication Number
WO 2004/009080 A1

(51) International Patent Classification⁷: **A61K 31/365**,
31/429, 9/08, A61P 33/10

(21) International Application Number:
PCT/NZ2003/000157

(22) International Filing Date: 21 July 2003 (21.07.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
520295 19 July 2002 (19.07.2002) NZ

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designation US
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designation US
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designation US
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designation US
- of inventorship (Rule 4.17(iv)) for US only

Published:

- with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(71) Applicant (*for all designated States except US*): **ASH-MONT HOLDINGS LIMITED** [NZ/NZ]; First Floor, 17 Shea Terrace, Takapuna, 1309 Auckland (NZ).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **HOLMES, Robert, William, Lachlan** [NZ/NZ]; 15 Calman Place, Birkenhead, 1310 Auckland (NZ). **RAZZAK, Majid, Hameed, Abdul (Dr)** [NZ/NZ]; 59 Blue Bird Crescent, Albany, 1311 Auckland (NZ). **JINDAL, Kour, Chand (Dr)** [IN/IN]; Flat No 7, 4th Floor, No 8, 4th Avenue, Indira Nagar, Adyar, Chennai, 600 020 Tamilnadu (IN). **NILENDU, Sen** [IN/IN]; C-18, Nathans Complex, East Coast Road, Thiruvanniyur, Chennai, 600 041 Tamilnadu (IN).

(74) Agents: **PIPER, James, William et al.**; **PIPERS**, Level 1, 29 Waterloo Road, 6009 Lower Hutt (NZ).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

(54) Title: Levamisole, Avermectins or similar in pyrrolidone solvent

(57) Abstract: A stable formulation which is suitable for administration to animals is claimed. The formulation includes at least one active selected from the group comprising avermectins and milbemycins and levamisole. Both of the said actives are dissolved in a pyrrolidone solvent.

BEST AVAILABLE COPY

LEVAMISOLE, AVERMECTINS OR SIMILAR IN PYRROLIDONE SOLVENT

DT09 Rec'd PCT/PTO 1.8 JAN 2005

FIELD OF THE INVENTION

10 This invention relates to the field of veterinary pharmaceuticals and in particular to anthelmintic formulations including a combination of actives.

BACKGROUND

15 Anthelmintics are an important tool for farmers seeking to improve the productivity of grazing cattle. The first class of modern broad-spectrum anthelmintic was the benzimidazoles introduced in the early 1960's, followed by levamisole and morantel in the late 1960's and finally the avermectins and milbemycins in the early 1980's.

<i>Anthelmintic</i>	<i>Year of Introduction</i>	<i>Main Active's in the Group</i>
Benzimidazoles	Early 1960's	Thiabendazole, albendazole, fenbendazole, oxfendazole
Levamisole/Morantel	Late 1960's	Levamisole, morantel
Avermectins/Milbemycins	Early 1980's	Abamectin, ivermectin, moxidectin, doramectin, eprinomectin

20 Parasite resistance has developed to each group of anthelmintic since they were introduced. Resistance to benzimidazole-based drenches is widespread throughout the world. Cases have been reported that involve resistance in all three major cattle parasites species: *Ostertagia*, *Trichostrongylus* and *Cooperia*.

25 Resistance to levamisole/morantel based drenches is well known but is less widespread than benzimidazole resistance.

30 In 1995, New Zealand researchers reported a strain of the worm parasite *Cooperia* that was resistant to both ivermectin (a member of the avermectin/milbemycin group) and to oxfendazole (a benzimidazole). In 1996, reports were published of an ivermectin resistant *Cooperia* strain that was cross-resistant to doramectin and moxidectin (also members of the avermectin/milbemycin group).

5 To prevent and manage the problem of anthelmintic resistance farmers have relied on various number of strategies including:

- minimizing anthelmintic use by only treating at strategically important times
- alternating the type of anthelmintic used
- 10 - using combinations of anthelmintics from different groups to reduce the potential of parasites to survive the treatment.

Orally administered combinations of benzimidazole and levamisole anthelmintics are well known, and have been used for many years.

15

However in recent years products based on actives selected solely from the avermectin/milbemycin groups have held the most significant share of the cattle anthelmintic market due to their high efficacy against the major production limiting parasite species, *Ostertagia*. The availability of easy to apply topical pour-on formulations has further
20 extended their market dominance.

By contrast, levamisole-based products have been used on a much more limited basis. Despite their having good efficacy against *Cooperia*, the key dose limiting parasite of the avermectin/milbemycin group.

25

The table below shows that while each anthelmintic group has particular limitations against certain parasites, a combination of actives selected from the avermectin/milbemycin and levamisole groups would achieve two highly important goals:

- high efficacy against the key cattle parasites
- 30 - combination potency to help prevent parasites surviving the treatment

<i>Anthelmintic Class</i>	<i>Cooperia Efficacy</i>	<i>Ostertagia Efficacy</i>
Levamisole	Good	Poor
Avermectin/Milbemycin	Poor	Good
Combination of both classes	Good	Good

Despite this rationale for an easy to use product combining levamisole active with an avermectin/milbemycin active combinations have been difficult to formulate.

5 Previous attempts included the formulation of a double active formulation including levamisole and niclosamide. This was designed to target tapeworm and roundworm. This formulation however, was unsatisfactory as exposure to water made it too viscous to use.

Further it was found the differing pH requirements of levamisole and other anthelmintics
10 made it difficult to formulate a stable product.

NZ 336139 represents a recent attempt to formulate a combination avermectin/milbemycin and levamisole product.

15 To achieve co-existence within the formulation Nufarm relies on emulsion technology. The emulsion includes formulation including the levamisole in aqueous acidic phase and including an anthelmintic such as an avermectin or milbemycin in the lipophilic phase. A third active can be suspended in particulate form in the aqueous phase.

20 The disadvantage of this formulation is the need for the formulation to be shaken or agitated into an emulsion. In addition, the product is chemically complicated including 2 or 3 different phases.

The complicated nature of the formulation in NZ 336139 is due in part to the different
25 formulation requirements of the actives. Avermectins and milbemycins being substantially insoluble in water whereas levamisole is water soluble. In addition, levamisole has previously been found to require a pH of less than about 4 for stability while avermectins and milbemycin require a pH of about 6.6.

30 As this will be appreciated, in addition to the stability issues topical formulations have a tendency to cause skin irritation to the animal at the site of application. Accordingly, a formulation to be acceptable for topical use it must not cause excessive skin irritation.

Accordingly, there is a need for a stable, formulation capable of stably including avermectins
35 or milbemycins together with levamisole.

In addition, it is desirable the formulation be suitable for topical use.

5

OBJECT

It is an object of the present invention to provide a stable anthelmintic formulation or one that will at least provide the public with a useful choice.

10

STATEMENT OF INVENTION

In one aspect the invention relates to a stable formulation suitable for administration to animals including at least 2 actives wherein a first of the actives is selected from the group including the avermectins and the milbemycins and the second of said actives is levamisole, said actives being dissolved in a pyrrolidone solvent.

Preferably the formulation may additionally include a co-solvent selected from the glycol ether group.

Preferably the avermectin or milbemycin is selected from the group including abamectin, doramectin, eprinomectin, ivermectin and moxidectin.

Preferably the pyrrolidone solvent is N-methyl pyrrolidone or 2-pyrrolidone.

More preferably the avermectin or milbemycin is present in the range of between 0.01 – 5% w/v.

Preferably levamisole is present in the range of between 1 – 30% w/v.

Preferably the formulation additionally includes at least one further medicament selected from the group comprising anthelmintics, dietary supplements, vitamins, mineral and other beneficial agents.

More preferably wherein the formulation additionally includes excipients including preservatives, stabilisers, flavorants, co solvents.

Preferably the formulation is suitable for topical, injectable or oral administration.

More preferably the formulation is suitable for topical administration.

- 5 More preferably the formulation does not cause unacceptable levels of skin irritancy when applied topically.

In a further related aspect the invention relates to a method of treating or preventing infection of cattle with *Cooperia* or *Ostertagia* by administering a formulation of the present invention.

- 10 The formulations of the present invention must be stable to be of commercial use. In this specification, a commercially acceptable anthelmintic formulation is one which is stable at room temperature for a period of at least 6 months. In conditions of accelerated testing, at 40°C, this requires the potency of the actives within the formulation to remain within specified and acceptable limits for 3 months.

- 15 Avermectins and milbemycins where used in this specification refer to a group of actives having anthelmintic activity. The avermectin group includes by way of example, avermectin, ivermectin, doramection and eprinomectin. The milbemycin group includes moxidectin.

- 20 Pyrrolidones solvents useable in this invention include, N-methyl-2-pyrrolidone, 2-pyrrolidone, 1-pyrrolidone, N-ethylene-2-pyrrolidone, 3, 3-dimethyl-2-pyrrolidone, N-ethyl-2-pyrrolidone, 5-dimethyl-2-pyrrolidone, N-ethoxy-2-pyrrolidone, and combinations thereof.

Levamisole is used in this specification includes levamisole base, levamisole phosphate together with other salts and forms.

- 25 The invention the subject of the present application is advantageous as it provides stable formulations including an avermectin or milbemycin in combination with levamisole. Further, the formulations retain each active in solution.

- 30 The formulations are monophasic and suitable to manufacture on a commercial scale. In addition, as both actives are in solution the formulations are physically stable. In that it does not separate out into separate phases either aqueous and lipophilic phases or liquid and solid phases. This enables the formulations the subject of this application to be used without requiring agitation or shaking before use and greatly reduces the risk of differing concentrations of actives through the drum or other storage container.

- 5 In addition, as the formulation excludes water the issue of incompatible pH requirements is alleviated. Enabling the two actives to stability co-exist in a single phase.

DESCRIPTION

- 10 A large number of studies were undertaken over a 4 year period to develop a stable anthelmintic formulation combining levamisole and avermectin/milbemycin. In these studies abamectin was used as the representative avermectin/milbemycin active, whilst levamisole, in its base form, was used as the representative levamisole/morantel active.

15 Study 1

A number of potential formulations were prepared using a soya bean oil base and common excipients used in the preparation of topical anthelmintics.

20

Formulation 1		Formulation 2	
Materials	%w/v	Materials	%w/v
Abamectin	1	Abamectin	1
Levamisole	20	Levamisole	20
Benzyl alcohol	5	Benzyl alcohol	5
Capmul PG-8	20	Capmul PG-8	20
Isopropyl Palmitate	10	Isopropyl Myristate	10
Tween 80	2	Tween 80	2
Soya bean oil	q.v.	Soya bean oil	q.v.

Formulation 3		Formulation 4	
Materials	%w/w	Materials	%w/w
Abamectin	1	Abamectin	1
Benzyl alcohol	5	Levamisole	20
Capmul PG-8	20	Benzyl alcohol	5
Isopropyl Palmitate	10	Capmul PG-8	20
Tween 80	2	Isopropyl Myristate	10
Soya bean oil	q.v.	Soya bean oil	q.v.

- 25 None of these formulations were stable when tested under conditions of elevated temperature. All formulations exhibited significant degradation of the abamectin component. Animal studies also demonstrated an unexpected degree of skin irritancy with hair loss at the point of application. These results indicated that an oil-base to the product may be unsuitable both from an irritancy and stability perspective.

30

5 Study 2

A number of formulations were prepared using propylene glycol and glycol ethers, both common excipients used in veterinary drug formulation. These were then subjected to conditions of elevated temperature to determine their potential shelf stability. As a positive control for stability testing purposes a commercially available avermectin/milbemycin product, Ivomec® Plus Injection was used.

Formulations

	R20	R27	R28	R29	Ivomec®	Levipor®	Ivomec® Plus injection
Lev.base	20.0 g	20.0 g	20.0 g	20.0 g	--	20.0 g	--
Abamectin	1.0 g	1.0 g	1.0 g	1.0 g	--	--	--
Ivermectin	--	--	--	--	0.5 g	--	3.0 g
Propylene Glycol	50 g	41 g	50 g	41 g			
Benzyl alcohol	--	--	10 g	10 g			
BHT	0.2 g	0.2 g	0.2 g	0.2 g			
IPA	--	4 g	--	4 g			
*DGMEEE to	100ml	100ml	100ml	100ml	* No more details		

15 *DGMEEE: Diethylene glycol monoethyl ether (Transcutol®)

Stability results

		0 day	5d /60°C	10d /60°C	15d /60°C	20d /60°C	25d /60°C
R20	Lev.base	100%	93.1%	92.0%	88.4%	84.9%	83.2%
	Aba	100%	86.9%	67.0%	66.5%	46.9%	34.5%
R27	Lev.base	100%	88.1%	83.6%	83.8%	83.2%	79.9%
	Aba	100%	80.7%	76.9%	67.2%	58.5%	51.0%
R28	Lev.base	100%	85.7%	82.1%	82.7%	79.5%	75.3%
	Aba	100%	81.4%	64.4%	56.5%	45.2%	39.9%
R29	Lev.base	100%	88.3%	85.6%	88.3%	85.2%	81.3%
	Aba	100%	92.2%	72.3%	63.9%	52.2%	44.5%
Ivomec®	Ivermectin	100%	99.9%	--*	--*	--*	--*
Levipor®	Lev.base	100%	82.0%	--*	--*	--*	--*
Ivomec® Plus injection	Ivermectin	100%	97.9%	93.1%	91.7%	95.9% (?)	90.7%

*: solvent evaporated

20

In all test formulations at elevated temperatures the abamectin component degraded significantly over the period of the study. The ivermectin component of the commercially

- 5 available Ivomec® Plus formulation did not deteriorate to anywhere near the same extent as the abamectin component of the test formulations.

Whilst the levamisole component also deteriorated it did so at a much lower rate.

- The study once again demonstrated the difficulty of combining the two actives and that the
10 presence of levamisole was very problematic in preparing the combination formulation.

Study 3

- A further range of formulations were prepared in which benzyl alcohol was used to solubilise
15 the abamectin component of the formulations.

Formulations

Ingredients	Concentration (% w/v)					
	029/0	029/1	029/2/BH T	029/3/BH T	029/4/BH A	029/5/BH A
Lev.base	20.0	20.0	20.0	20.0	20.0	20.0
Abamectin	1.0	1.0	1.0	1.0	1.0	1.0
Propylene Glycol	41.0	41.0	41.0	41.0	41.0	41.0
Benzyl Alcohol	--	15.0	15.0	15.0	15.0	15.0
Isopropyl myristate	4.0	4.0	4.0	4.0	4.0	4.0
BHT	--	--	0.2	1.0	--	--
BHA	--	--	--	--	0.2	1.0
Diethylene glycol monoethyl ether to	100ml	100ml	100ml	100ml	100ml	100ml

20

Stability results

		0 day	20d /60°C	25d /60°C	30d /60°C	1 Month /37°C	2 Month /37°C	3 Month /37°C
029/0	Lev.base	100%	91.0%	90.1%	88.2%	95.0%	100.9%	ND
	Abamectin	100%	41.5%	36.3%	28.1%	91.3%	79.9%	ND
029/1	Lev.base	100%	76.3%	78.7%	75.1%	96.3%	89.4%	ND
	Abamectin	100%	42.1%	35.3%	31.5%	102.4%	65.8%	ND
029/2/BHT	Lev.base	100%	83.2%	74.4%	70.9%	95.4%	103.5%	ND
	Abamectin	100%	45.3%	31.0%	31.8%	94.6%	62.8%	ND

029/3BHT	Lev.base	100%	84.1%	78.1%	70.2%	96.8%	90.8%	ND
	Abm	100%	46.2%	36.1%	32.8%	96.2%	50.2%	ND
029/4/BHA	Lev.base	100%	82.8%	73.6%	73.2%	96.9%	91.7%	ND
	Abm	100%	46.7%	34.9%	34.0%	96.5%	51.0%	ND
029/5/BHA	Lev.base	100%	85.0%	77.9%	74.5%	100.4%	94.1%	ND
	Abm	100%	47.8%	36.9%	33.0%	100.9%	53.2%	ND
Ivomec®	Iver	100%	95.0%	98.0%	101.3%	100.3%	100.3%	ND
Levipor®	Lev.base	100%	102.0%	102.9%	100.9%	104.5%	94.9%	ND

5

In the stability study the presence of benzyl alcohol did not have any significant effect in minimizing the rate of degradation of the abamectin component of the formulations. BHA and BHT also did not offer any advantage as stabilizing aids.

10 Study 4

A study was undertaken to determine whether the use of propylene glycol or glycol ethers would have any advantage in stabilizing the formulations.

15 Two formulations were prepared these are shown in the table below.

Formulations

	R 3	R 4
Levamisole base	20.0 g	20.0 g
Abamectin	1.0 g	1.0 g
Propylene glycol	--	40 ml
*DGBE to	100 ml	100 ml

*DGBE: Diethylene glycol n-butyl ether (Butyl carbitol®)

20

Stability results

		0 day	5 d/60°C	10 d/60°C	15 d/60°C	20 d/60°C
R3	Lev.base	100%	98.2%	99.0%	104.3%	100.5%
	Abm	100%	75.5%	67.3%	60.6%	52.8%
R4	Lev.base	100%	96.6%	100.6%	89.3%	95.5%
	Abm	100%	67.8%	49.6%	33.5%	33.4%

While levamisole base was relatively stable in both formulations the abamectin degraded in both formulations with the rate of degradation much more significant in the formulation that included propylene glycol. This suggested that propylene glycol was probably not beneficial in enhancing the stability of abamectin when used with DGBE.

25

5 Study 5

A study was undertaken to attempt to improve the stability of formulations that used DGBE as their base.

10 Formulations

	3-1	3-2	3-3
Aba	1.0 g	1.0 g	1.0 g
Leva.base	20.0 g	20.0 g	20.0 g
BHT	--	0.2 g	2.0 g
*DGBE to	100 ml	100 ml	100 ml

*DGBE: Diethylene Glycol n-butyl Ether

Stability results

15

		0 days	10days/60°C	20days/60°C	30days/60°C
3-1	Lev.base	100%	94.2%	96.7%	92.8%
	Aba	100%	63.8%	54.1%	40.1%
3-2	Lev.base	100%	96.8%	97.9%	91.5%
	Aba	100%	75.1%	55.9%	33.5%
3-3	Lev.base	100%	98.0%	91.1%	89.6%
	Aba	100%	73.9%	52.6%	41.1%

The study demonstrated that both BHT and BHA had no significant effect on enhancing the stability of the abamectin component of the formulation.

20 Study 6

Alternate formulations that used benzoic acid and/or BHT were prepared to evaluate their effects on the stability of DGBE based formulations.

Formulations

25

	R1	R2	R3	R4	R5	R6
Lev.base	20.0 g	20.0 g	20.0 g	20.0 g	20.0 g	20.0 g
Abamectin	1.0 g	1.0 g	1.0 g	1.0 g	1.0 g	1.0 g
BHT	--	--	--	0.2 g	0.2 g	0.2 g
Benzoic acid	--	0.05 g	0.2 g	--	0.05 g	0.2 g
*DGBE to	100 ml	100 ml	100 ml	100 ml	100 ml	100 ml

*DGBE: Diethylene Glycol n-butyl Ether

5 Stability results

		0 day	10d /60°C	20d /60°C	30d /60°C	1 Month /37°C	2 Month /37°C	3 Month /37°C
R1	Lev.base	100%	100.4%	98.9%	99.0%	98.7%	98.2%	98.6%
	Aba	100%	65.5%	46.1%	34.5%	88.4%	72.0%	50.6%
R2	Lev.base	100%	99.4%	98.7%	98.6%	97.9%	97.3%	96.6%
	Aba	100%	59.5%	42.5%	36.6%	71.4%	62.7%	56.6%
R3	Lev.base	100%	100.2%	103.2%	101.3%	102.4%	101.2%	102.4%
	Aba	100%	58.5%	39.1%	44.1%	85.3%	73.9%	62.8%
R4	Lev.base	100%	100.1%	98.7%	99.5%	100.2%	101.1%	100.2%
	Aba	100%	67.5%	33.7%	24.1%	93.7%	62.2%	55.2%
R5	Lev.base	100%	99.6%	99.1%	98.4%	99.2%	98.9%	99.5%
	Aba	100%	52.1%	39.0%	27.7%	79.0%	61.7%	55.2%
R6	Lev.base	100%	100.1%	100.7%	99.2%	103.4%	101.2%	101.1%
	Aba	100%	53.5%	49.7%	39.9%	68.6%	62.1%	47.7%

The stability of Abamectin showed no improvement with the use of benzoic acid or BHT.

Study 7

10

A selection of new formulations that included other excipients with DGBE were prepared.

Formulations

	R3	R4	R5	R6
Lev.base	20.0g	15.0g	20.0g	20.0g
Lev.HCl	--	5.0g	--	--
Aba	1.0g	1.0g	1.0g	1.0g
β-CD	0.5g	--	--	--
Benzoic acid	--	--	5.0g	--
Citric acid	--	--	--	3.0g
Propylene Glycol	40ml	40ml	--	--
Glycerin Formal	30ml	30ml	--	--
Capmul MCM	--	to 100ml	--	--
DGBE	to 100ml	--	to 100ml	to 100ml

15

DGBE: Diethylene glycol n-butyl ether

	R7	R8	R9	R10	R11-1	R11-2	R12	R13	R14	R15
Lev.base	20.0 g	20.0 g	20.0 g	20.0 g	20.0 g	20.0 g	20.0 g	20.0 g	20.0 g	20.0 g
Aba	1.0g	1.0g	1.0g	1.0g	1.0g	1.0g	1.0g	1.0g	1.0g	1.0g
TEA	--	--	--	1.0m l	--	--	1.0m l	1.0m l	--	--

EDTA	--	--	--	--	0.01 g	--	0.01 g	0.01 g	0.01 g	0.01 g
EDTA- 2Na	--	--	--	--	--	0.01 g	--	--	--	--
BHT	--	--	--	--	2.0g	2.0g	2.0g	--	2.0g	--
BHA	--	--	--	--	--	--	--	2.0g	--	2.0g
Benzoic acid	--	--	--	--	--	--	--	--	5.0g	5.0g
DGMEE	to 100 ml	--	--	to 100 ml	to 100 ml	to 100 ml	To 100 ml	to 100 ml	to 100 ml	to 100 ml
DGBE	--	to 100 ml	--	--	--	--	--	--	--	--
DPM	--	--	to 100 ml	--	--	--	--	--	--	--

- 5 TEA: Triethylamine; EDTA: Ethylenediaminetetraacetic acid; BHT: Butylated Hydroxy Toluene; BHA: Butylated Hydroxyanisole; DGMEE: Diethylene glycol monoethyl ether; DGBE: Diethylene glycol n-butyl ether; DPM: Dipropylene glycol methyl ether

Stability results

10

		0 day	10days/60°C	20days/60°C	30days/60°C
R3	Lev.base	100%	99.5%	100.9%	100.9% (?)
	Aba	100%	58.7%	36.5%	37.8%
R4	Lev.base	100%	99.7%	98.8%	98.4%
	Aba	100%	58.6%	35.5%	24.0%
R5	Lev.base	100%	99.5%	90.6%	70.0%
	Aba	100%	76.2%	49.5%	42.7%
R6	Lev.base	100%	98.9%	69.5%	52.4%
	Aba	100%	70.9%	64.7%	69.4% (?)
R7	Lev.base	100%	101.1%	100.6%	100.4%
	Aba	100%	60.6%	36.5%	26.6%
R8	Lev.base	100%	99.9%	100.1%	101.0%
	Aba	100%	64.2%	52.9%	40.4%
R9	Lev.base	100%	101.4%	100.2%	98.8%
	Aba	100%	60.1%	55.4%	46.9%
R10	Lev.base	100%	94.0%	99.3%	101.7%
	Aba	100%	52.0%	37.5%	25.6%
R11-1	Lev.base	100%	101.7%	99.2%	98.3%
	Aba	100%	67.0%	40.2%	27.3%
R11-2	Lev.base	100%	106.9% (?)	100.1%	97.8%
	Aba	100%	63.3%	57.1%	38.8%
R12	Lev.base	100%	97.0%	98.8%	100.1%
	Aba	100%	53.0%	33.5%	28.3%

R13	Lev.base	100%	94.9%	99.8%	99.8%
	Aba	100%	53.3%	35.7%	28.2%
R14	Lev.base	100%	64.5%	89.4% (?)	70.6%
	Aba	100%	56.1%	38.4%	23.7%
R15	Lev.base	100%	79.7%	96.0% (?)	82.9%
	Aba	100%	67.6%	38.9%	30.2%

None of the formulations showed great promise in stabilizing the abamectin component of the formulations.

Study 8

A selection of new formulations that included other excipients with DGMEE were prepared.

Formulations

	F1	F2	F3	F4	F5	F6	F7	F8
Lev.base	20.0g	20.0g	20.0g	20.0g	20.0g	20.0g	20.0g	20.0g
Abamectin	1.0g	1.0g	1.0g	1.0g	1.0g	1.0g	1.0g	1.0g
TEA	--	1.0ml	1.0ml	--	1.0ml	1.0ml	--	--
EDTA	--	--	--	--	--	--	0.01g	0.01g
H ₂ O	--	--	--	10g	10g	10g	--	10g
BHT	--	--	--	--	--	--	2.0g	2.0g
BHA	--	--	--	--	--	--	--	--
Benzoic Acid	5.0g	--	5.0g	5.0g	--	5.0g	--	--
DGMEE to	100ml	100ml	100ml	100ml	100ml	100ml	100ml	100ml

TEA: Triethylamine; EDTA: Ethylenediaminetetraacetic acid; BHT: Butylated Hydroxy Toluene; BHA: Butylated Hydroxyanisole; DGMEE: Diethylene glycol monoethyl ether

Stability results

		0 day	10 days/60°C	20 days/60°C	30 days/60°C
F1	Lev.base	100%	99.6%	78.3%	63.8%
	Aba	100%	69.5%	38.5%	30.3%
F2	Lev.base	100%	100.3%	100.3%	104.6% (?)
	Aba	100%	75.4%	50.7%	41.2%
F3	Lev.base	100%	99.7%	99.9%	87.7%
	Aba	100%	52.3%	49.8%	26.9%
F4	Lev.base	100%	34.4%	9.2% (?)	8.2% (?)
	Aba	100%	64.0%	52.8%	46.1%
F5	Lev.base	100%	100.2%	97.2%	47.7%
	Aba	100%	32.7%	No peak	No peak
F6	Lev.base	100%	47.9%	40.1%	34.5%
	Aba	100%	63.2%	55.5%	45.4%

F7	Lev.base	100%	100.1%	99.0%	102.6%
	<i>Abu</i>	100%	72.6%	67.6%	53.9%
F8	Lev.base	100%	100.3%	99.3%	98.1%
	<i>Abu</i>	100%	53.6%	26.8% (?)	No peak

Once again none of the formulations showed great promise in stabilizing the abamectin component of the formulations.

Study 9

Further alternate formulations were prepared according to table below.

Formulations

	R1	R2	R3	R4	R5	R6
Lev.base	20.0g	20.0g	20.0g	20.0g	20.0g	20.0 g
Abamectin	1.0g	1.0g	1.0g	1.0g	1.0g	1.0g
Benzoic Acid	5.0g	5.0g	5.0g	10.0g	--	--
Acetic acid	--	--	--	--	2.0ml	4.0ml
BHA	--	--	2.0g	--	--	--
DGMEE to	100ml	--	--	--	--	--
DGBE to	--	100ml	100ml	100ml	100ml	100ml

BHA: Butylated Hydroxyanisole; DGMEE: Diethylene glycol monoethyl ether; DGBE:

Diethylene glycol n-butyl ether

Stability results

		0 day	10 days/60°C	20 days/60°C	30 days/60°C*
R1	Lev.base	100%	105.8% (?)	85.5%	79.4%
	<i>Abu</i>	100%	58.1%	38.2%	31.0%
R2	Lev.base	100%	98.9%	73.9%	68.4%
	<i>Abu</i>	100%	71.1%	44.3%	43.6%
R3	Lev.base	100%	98.5%	73.5%	61.2%
	<i>Abu</i>	100%	83.8%	47.7%	38.8%
R4	Lev.base	100%	90.7%	69.0%	50.6%
	<i>Abu</i>	100%	53.1%	48.7%	40.6%
R5	Lev.base	100%	100.0%	99.1%	100.4%
	<i>Abu</i>	100%	70.0%	48.5%	28.4%
R6	Lev.base	100%	99.8%	99.6%	99.3%
	<i>Abu</i>	100%	57.6%	52.4%	

*The temperature in oven was changed into 55°C after stored for 20days.

However none of these demonstrated great promise in stabilizing the abamectin component of the formulations.

5

Study 10

Example formulations were prepared according to the table below.

10 **Formulations**

	R1	R2	R3	R4	R5
Lev.base	20.0 g	20.0 g	20.0 g	20.0 g	20.0 g
Abamectin	1.0 g	1.0 g	1.0 g	1.0 g	1.0 g
Acetic acid	--	2.0 ml	4.0 ml	6.0 ml	10.0 ml
*DGBE to	100 ml	100 ml	100 ml	100 ml	100 ml

*DGBE: Diethylene glycol n-butyl ether

Stability results

15

		0 day	10 days/60°C	20 days/60°C	30 days/60°C
R1	Lev.base	100%	99%	97%	96%
	Abamectin	100%	85%	79%	58%
R2	Lev.base	100%	82%	67%	50%
	Abamectin	100%	76%	71%	51%
R3	Lev.base	100%	78%	60%	40%
	Abamectin	100%	77%	72%	53%
R4	Lev.base	100%	52%	46%	23%
	Abamectin	100%	83%	85%	73%
R5	Lev.base	100%	55%	46%	19%
	Abamectin	100%	73%	67%	55%

Formulations containing acetic acid did not improve the stability of abamectin. However, the stability of levamisole base was adversely affected to a significant extent.

20 **Study 11**

A trial was carried out to determine whether the addition of varying levels of N-Methyl-2-Pyrrolidone (Pharmasolv) to DGBE would enhance stability. All the formulations were kept at 60°C and were analysed to assess the extent of degradation after 7, 14 and 30 days.

25

Formulations

	G1	G2	G3	G4	G5
Lev.base	20.0% w.v.	20.0% w/v	20.0% w/v	20.0% w/v	20.0% w/v
Abamectin	1.15% w/v	1.15% w/v	1.15% w/v	1.15% w/v	1.15% w/v
DGBE	-	25% w/v	40% w/v	q.v.	q.v.
N-Methyl-2-Pyrrolidone	q.v.	q.v	q.v	25%	-

5

Stability Results

Form.	Initial		7 days at 60°C		14 days at 60°C		1 month at 60°	
	Abamectin	Levamisole	Abamectin	Levamisole	Abamectin	Levamisole	Abamectin	Levamisole
G1	96.12	101.43	93.04	95.55	89.57	89.75	79.13	86.95
G2	100.24	103.22	95.65	99.50	95.65	96.35	79.13	93.60
G3	103.30	102.58	93.91	97.00	87.83	95.20	66.96	92.85
G4	109.05	101.70	101.74	99.95	93.91	99.35	66.57	93.80
G5	89.42	100.32	83.48	97.80	80.00	93.30	57.39	89.55

10

The stability results of the solution containing both the actives in Pharmasolv demonstrated that surprisingly a pyrrolidone based formulation was capable of significantly slowing the rate of degradation of both levamisole and abamectin.

- 15 To further confirm the findings of this study new batches were prepared with the formulation as specified in the following table:

<i>Material</i>	<i>Formulation</i>
Lev.base	20.0% w/v
Abamectin	1.15% w/v
DGBE	25% w/v
N-Methyl-2-Pyrrolidone	q.v

- 20 Stability results over a twelve month period of storage at 25°C confirmed the increased stability of an abamectin/levamisole formulation containing N-Methyl-2-Pyrrolidone (Pharmasolv) and DGBE.

<i>ACTIVE</i>	<i>Initial</i>	<i>6 Month</i>	<i>12 Months</i>
Abamectin	104.00	102.55	99.95
Levamisole	99.75	99.00	98.55

25

5 Field Studies

The formulation of the table above containing DGBE and N-methyl-2-pyrrolidone was used in a slaughter study to evaluate the effectiveness of the formulation relative to formulations containing either levamisole or an avermectin or milbemycin. The results clearly demonstrated that whilst the levamisole-based formulation (Levipor®) performed poorly against *Ostertagia* and the eprinomectin-based formulation (Eprinex®) performed poorly against *Cooperia*, the abamectin/levamisole combination showed outstanding efficacy against all parasite species.

A large number of field studies on cattle of all ages have also confirmed that in contrast with a number of the other test formulations there is no skin irritation on treated animals.

Table 1: Geometric mean total worm counts for calves treated with Abamectin / levamisole pour-on, Eprinex® pour-on or Levipor® pour-on in comparison with an untreated control group.

Treatment	Control	Abm/Lev PO	Eprinex® PO	Levipor® PO
<i>Ostertagia</i> (adult)	11435.5 ^a	4.4 ^b	17.3 ^b	5808.1 ^a
<i>Ostertagia</i> (immature)	1274 ^a	2.3 ^b	0 ^b	1317.4 ^a
<i>T. axei</i> (adult)	996.7 ^a	0 ^b	0 ^b	110.9 ^a
<i>T. axei</i> (immature)	4.7 ^a	0 ^a	0 ^a	1.9 ^a
<i>Trichostrongylus</i> spp (mature)	744.3 ^a	6.7 ^b	46.4 ^a	5 ^b
<i>Cooperia</i> (adult)	15948.8 ^a	1.9 ^b	2155.8 ^a	5.9 ^b
<i>Cooperia</i> (immature)	1598.7 ^a	1.9 ^b	5.7 ^b	1.9 ^b
<i>Oesophagostomum</i> (mature)	2.5 ^a	0 ^a	0 ^a	0 ^a
<i>Trichuris</i> (mature)	35.4 ^a	0 ^b	0 ^b	0 ^b

^a means within the same row with different superscripts are significantly different at $p < 0.05$

Table 2: Treatment efficacies based on group geometric mean total worm counts.

Treatment	Abm/Lev PO	Eprinex® PO	Levipor® PO
<i>Ostertagia</i> (adult)	>99.9%	99.8%	49.2%
<i>Ostertagia</i> (immature)	99.8%	>99.9%	0%
<i>T. axei</i> (adult)	>99.9%	>99.9%	80.1%
<i>T. axei</i> (immature)	>99.9%	>99.9%	>99.9%
<i>Trichostrongylus</i> spp (mature)	99.1%	93.7%	99.3%
<i>Cooperia</i> (adult)	>99.9%	86.5%	>99.9%

<i>Cooperia</i> (immature)	99.8%	99.6%	99.9%
<i>Oesophagostomum</i> (mature)	>99.9%	>99.9%	>99.9%
<i>Trichuris</i> (mature)	>99.9%	>99.9%	>99.9%

5

PREFERRED EMBODIMENTS

In the preferred embodiments the formulations of the invention there include avermectin or milbemycin in combination with levamisole and a pyrrolidone solvent. A glycol ether may additionally be included.

10

The following examples are provided as examples only and are in no way intended to limit the spirit or scope of the invention.

15

Example Formulations

The formulations of the present invention are prepared as follows:

1. Add levamisole base, avermectin/milbemycin and pyrrolidone to a mixing vessel.
2. Stir at room temperature until the actives have completely dissolved.
3. Add the glycol ether, if desired, and mix well.
4. Add the pyrrolidone to volume and continue mixing until a clear solution is obtained.

20

Topical Formulations

25

1. Examples of topically applied formulations of the invention include:

Formulation 1.1

<i>Ingredient</i>	<i>% w/v</i>
Abamectin	1%
Levamisole Base	20%
n-methyl pyrrolidone	q.v.

30

Formulation 1.2

<i>Ingredient</i>	<i>% w/v</i>
Ivermectin	0.5%
Levamisole Base	10%

n-methyl pyrrolidone	q.v.
----------------------	------

5

Formulation 1.3

<i>Ingredient</i>	<i>% w/v</i>
Ivermectin	0.5%
Levamisole Base	10%
DGMBE	25%
n-methyl pyrrolidone	q.v.

Formulation 1.4

10

<i>Ingredient</i>	<i>% w/v</i>
Eprinomectin	1.0%
Levamisole Base	20%
DGMBE	25%
n-methyl pyrrolidone	q.v.

2. Examples of Injectable formulations include:**Formulation 2.1**

15

<i>Ingredient</i>	<i>% w/v</i>
Ivermectin	0.5%
Levamisole Phosphate	20%
2- pyrrolidone	q.v.

Formulation 2.2

<i>Ingredient</i>	<i>% w/v</i>
Moxidectin	0.5%
Levamisole Phosphate	20%
2 – pyrrolidone	q.v.

20 3. Examples of Orally administered formulations include:**Formulation 3.1**

<i>Ingredient</i>	<i>% w/v</i>
Abamectin	0.1%
Levamisole Base	5%
n-methyl pyrrolidone	q.v.

25 Formulation 3.2

<i>Ingredient</i>	<i>% w/v</i>
Ivermectin	1%
Levamisole Base	5%

5

n-methyl pyrrolidone	q.v.
----------------------	------

Formulation 3.3

<i>Ingredient</i>	<i>% w/v</i>
Abamectin	1%
Levamisole Base	20%
n-methyl pyrrolidone	q.v.

Formulation 3.4

10

<i>Ingredient</i>	<i>% w/v</i>
Abamectin	1%
Levamisole Base	20%
n-methyl pyrrolidone	q.v.

Formulation 3.5

<i>Ingredient</i>	<i>% w/v</i>
Abamectin	1%
Levamisole Base	20%
n-methyl pyrrolidone	q.v.

- 15 The rates for these formulations are generally in the order of 1ml to 5kg to 1ml per 20kg for oral administration, 1ml per 25 kg or 1ml per 50kg for administration by injection, and 1ml per 10kg or 1ml per 20kg for topical administration.

The methods of administration of the formulations are well known within the art.

20

5 **WE CLAIM:**

1. A stable formulation suitable for administration to animals including at least one active selected from the group comprising avermectins and milbemycins and levamisole and both of said actives being dissolved in a pyrrolidone solvent.
- 10 2. A stable formulation suitable for administration to animals as claimed in claim 1, additionally including a solvent selected from the glycol ethers.
3. A stable formulation suitable for administration to animals as claimed in any previous claim, wherein the pyrrolidone solvent is 2-pyrrolidone or N-methyl pyrrolidone.
4. A stable formulation suitable for administration to animals as claimed in any previous
15 claim, wherein the avermectin or milbemycin is present in the range of between 0.01 – 5% w/v.
5. A stable formulation suitable for administration to animals as claimed in claim 4, wherein the avermectin or milbemycin is selected from the group comprising abamectin, doramectin, eprinomectin, ivermectin and moxidectin.
- 20 6. A stable formulation suitable for administration to animals as claimed in any previous claim, wherein the levamisole is present in the range of between 1 – 30% w/v.
7. A stable formulation suitable administration to animals as claimed in any previous claim, wherein the formulation additionally includes at least one further medicament selected from the group comprising anthelmintics, dietary supplements, vitamins, mineral and
25 other beneficial agents.
8. A stable formulation suitable for administration to animals as claimed in any previous claim, wherein the formulation is suitable for topical administration.
9. A stable formulation suitable for administration to animals as claimed in any of claims 1 to 8, wherein the formulation is suitable for parenteral administration.
- 30 10. A stable formulation suitable for administration to animals as claimed in any of claims 1 to 8, wherein the formulation is suitable for oral administration.

- 5 11. A method of treating or preventing infection of cattle with *Cooperia* or *Ostertagia* by administering a formulation as claimed in any of claims 1-10.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/NZ03/00157

A. CLASSIFICATION OF SUBJECT MATTER					
Int. Cl. ⁷ : A61K 31/365, 31/429, 9/08; A61P 33/10					
According to International Patent Classification (IPC) or to both national classification and IPC					
B. FIELDS SEARCHED					
Minimum documentation searched (classification system followed by classification symbols)					
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched					
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) DWPI, Medline, CAPLUS: avermectin, ivermectin, eprinomectin, moxidectin, selamectin, abamectin, doramectin, milbemycin, avermectin, levamisole, +pyrrolidone					
C. DOCUMENTS CONSIDERED TO BE RELEVANT					
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.			
X	WO 97/26895 A (Komer G.) 31 July 1997, pages 3-9	1-5, 7-10			
X	US 6054140 A (Lamberti, J.C.) 25 April 2000 Columns 2-6	1-5, 7-10			
X	US 6340672 B (Mihalik, R.) 22 January 2002 Columns 1-10	1-5, 7-10			
X	WO 01/51028 A (Blue Ridge Pharmaceuticals) 19 July 2001 pages 5-11 & claims 4, 6, 11-15, 24, 26, 30, 31 and 42	1-5, 7-10			
<input type="checkbox"/> Further documents are listed in the continuation of Box C <input checked="" type="checkbox"/> See patent family annex					
<p>* Special categories of cited documents:</p> <table style="width: 100%;"> <tr> <td style="width: 33%;"> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier application or patent but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </td> <td style="width: 33%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p> </td> <td style="width: 33%;"></td> </tr> </table>			<p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier application or patent but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>	<p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p>	
<p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier application or patent but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>	<p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p>				
Date of the actual completion of the international search 29 October 2003		Date of mailing of the international search report - 7 NOV 2003			
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustalia.gov.au Facsimile No. (02) 6285 3929		Authorized officer G.J. McNEICE Telephone No : (02) 6283 2055			

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/NZ03/00157

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report		Patent Family Member					
WO	9726895	AU	17568/97	CA	2244843	GB	2326093
		US	5773422				
US	6054140	AU	59367/98	BR	9705242	EP	0867186
		NZ	330005	ZA	9801925		
US	6340672	AU	36949/01	EP	1299108	US	6492340
		WO	0160380				
WO	0151028	AU	30898/01				

END OF ANNEX

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.